S&P 500   4,267.52 (-0.38%)
DOW   33,665.02 (+0.27%)
QQQ   348.82 (-1.70%)
AAPL   177.82 (-0.78%)
MSFT   323.38 (-3.09%)
META   263.60 (-2.77%)
GOOGL   122.50 (-3.78%)
AMZN   121.23 (-4.25%)
TSLA   224.57 (+1.47%)
NVDA   374.75 (-3.05%)
NIO   7.76 (-1.52%)
BABA   85.28 (-1.64%)
AMD   117.83 (-5.15%)
T   16.10 (+2.74%)
F   13.59 (+5.10%)
MU   67.06 (-0.71%)
CGC   0.72 (-2.62%)
GE   106.08 (+0.59%)
DIS   92.52 (+0.39%)
AMC   4.73 (+1.94%)
PFE   38.89 (+1.36%)
PYPL   64.04 (-1.51%)
NFLX   399.77 (+0.12%)
S&P 500   4,267.52 (-0.38%)
DOW   33,665.02 (+0.27%)
QQQ   348.82 (-1.70%)
AAPL   177.82 (-0.78%)
MSFT   323.38 (-3.09%)
META   263.60 (-2.77%)
GOOGL   122.50 (-3.78%)
AMZN   121.23 (-4.25%)
TSLA   224.57 (+1.47%)
NVDA   374.75 (-3.05%)
NIO   7.76 (-1.52%)
BABA   85.28 (-1.64%)
AMD   117.83 (-5.15%)
T   16.10 (+2.74%)
F   13.59 (+5.10%)
MU   67.06 (-0.71%)
CGC   0.72 (-2.62%)
GE   106.08 (+0.59%)
DIS   92.52 (+0.39%)
AMC   4.73 (+1.94%)
PFE   38.89 (+1.36%)
PYPL   64.04 (-1.51%)
NFLX   399.77 (+0.12%)
S&P 500   4,267.52 (-0.38%)
DOW   33,665.02 (+0.27%)
QQQ   348.82 (-1.70%)
AAPL   177.82 (-0.78%)
MSFT   323.38 (-3.09%)
META   263.60 (-2.77%)
GOOGL   122.50 (-3.78%)
AMZN   121.23 (-4.25%)
TSLA   224.57 (+1.47%)
NVDA   374.75 (-3.05%)
NIO   7.76 (-1.52%)
BABA   85.28 (-1.64%)
AMD   117.83 (-5.15%)
T   16.10 (+2.74%)
F   13.59 (+5.10%)
MU   67.06 (-0.71%)
CGC   0.72 (-2.62%)
GE   106.08 (+0.59%)
DIS   92.52 (+0.39%)
AMC   4.73 (+1.94%)
PFE   38.89 (+1.36%)
PYPL   64.04 (-1.51%)
NFLX   399.77 (+0.12%)
S&P 500   4,267.52 (-0.38%)
DOW   33,665.02 (+0.27%)
QQQ   348.82 (-1.70%)
AAPL   177.82 (-0.78%)
MSFT   323.38 (-3.09%)
META   263.60 (-2.77%)
GOOGL   122.50 (-3.78%)
AMZN   121.23 (-4.25%)
TSLA   224.57 (+1.47%)
NVDA   374.75 (-3.05%)
NIO   7.76 (-1.52%)
BABA   85.28 (-1.64%)
AMD   117.83 (-5.15%)
T   16.10 (+2.74%)
F   13.59 (+5.10%)
MU   67.06 (-0.71%)
CGC   0.72 (-2.62%)
GE   106.08 (+0.59%)
DIS   92.52 (+0.39%)
AMC   4.73 (+1.94%)
PFE   38.89 (+1.36%)
PYPL   64.04 (-1.51%)
NFLX   399.77 (+0.12%)
NASDAQ:ROIV

Roivant Sciences (ROIV) Stock Forecast, Price & News

$9.75
0.00 (0.00%)
(As of 05:21 PM ET)
Compare
Today's Range
$9.64
$9.85
50-Day Range
$7.09
$9.75
52-Week Range
$2.87
$10.00
Volume
3.92 million shs
Average Volume
2.87 million shs
Market Capitalization
$7.39 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$12.80

Roivant Sciences MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
31.8% Upside
$12.80 Price Target
Short Interest
Bearish
3.50% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Selling Shares
$100.32 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.78) to ($1.25) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.13 out of 5 stars

Medical Sector

366th out of 982 stocks

Pharmaceutical Preparations Industry

175th out of 480 stocks


ROIV stock logo

About Roivant Sciences (NASDAQ:ROIV) Stock

Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company was founded in 2014 and is based in London, the United Kingdom.

Receive ROIV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Roivant Sciences and its competitors with MarketBeat's FREE daily newsletter.

ROIV Stock News Headlines

The single greatest medical breakthrough of all time?
We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.
Jefferies Keeps Their Buy Rating on Roivant Sciences (ROIV)
Sell Every Stock, Except ONE (Ticker Revealed)
We saw one of the longest bull markets in history, with the S&P surging well over 800% But now the chickens have come home to roost. However, Jeff Clark couldn’t care less because he ignores almost every single stock in the market.
Roivant Sciences (ROIV) Receives a Buy from H.C. Wainwright
Goldman Sachs Keeps Their Buy Rating on Roivant Sciences (ROIV)
Roivant Sciences (ROIV) Gets a Buy from H.C. Wainwright
See More Headlines

ROIV Price History

ROIV Company Calendar

Today
6/07/2023
Next Earnings (Estimated)
6/27/2023
Fiscal Year End
3/31/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ROIV
Fax
N/A
Employees
620
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$12.80
High Stock Price Forecast
$15.00
Low Stock Price Forecast
$10.00
Forecasted Upside/Downside
+31.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Net Income
$-845,260,000.00
Net Margins
-2,887.92%
Pretax Margin
-3,100.36%

Debt

Sales & Book Value

Annual Sales
$55.29 million
Book Value
$2.93 per share

Miscellaneous

Free Float
659,831,000
Market Cap
$7.41 billion
Optionable
Not Optionable
Beta
1.22

Key Executives

  • Mr. Vivek Ramaswamy (Age 37)
    Founder & Chairman
    Comp: $1.26M
  • Mr. Matthew Gline (Age 38)
    CEO & Director
    Comp: $1.45M
  • Dr. Eric Venker M.D. (Age 35)
    Pharm.D., Pres & COO
    Comp: $981.38k
  • Dr. Mayukh Sukhatme M.D. (Age 46)
    Pres & Chief Investment Officer
    Comp: $910.19k
  • Mr. Richard Pulik (Age 43)
    Chief Financial Officer
  • Ms. Rakhi Kumar (Age 42)
    Chief Accounting Officer
  • Dr. Huafeng Xu Ph.D.
    Chief Technology Officer
  • Mr. Josh Chen
    Gen. Counsel
  • Ms. Kelly Graff
    Head of People
  • Ms. Marianne L. Romeo (Age 54)
    Head of Global Transactions & Risk Management













ROIV Stock - Frequently Asked Questions

Should I buy or sell Roivant Sciences stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Roivant Sciences in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ROIV shares.
View ROIV analyst ratings
or view top-rated stocks.

What is Roivant Sciences' stock price forecast for 2023?

5 brokerages have issued 1-year target prices for Roivant Sciences' stock. Their ROIV share price forecasts range from $10.00 to $15.00. On average, they expect the company's stock price to reach $12.80 in the next twelve months. This suggests a possible upside of 31.0% from the stock's current price.
View analysts price targets for ROIV
or view top-rated stocks among Wall Street analysts.

How have ROIV shares performed in 2023?

Roivant Sciences' stock was trading at $7.99 at the start of the year. Since then, ROIV stock has increased by 22.3% and is now trading at $9.77.
View the best growth stocks for 2023 here
.

When is Roivant Sciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, June 27th 2023.
View our ROIV earnings forecast
.

What is Roivant Sciences' stock symbol?

Roivant Sciences trades on the NASDAQ under the ticker symbol "ROIV."

Who are Roivant Sciences' major shareholders?

Roivant Sciences' stock is owned by a number of retail and institutional investors. Top institutional investors include SB Investment Advisers UK Ltd. (10.95%), FMR LLC (4.06%), Wellington Management Group LLP (1.59%), State Street Corp (1.06%), BlackRock Inc. (0.82%) and Rubric Capital Management LP (0.74%). Insiders that own company stock include Eric Venker, Financial Lp Qvt, Matthew Gline, Pharma Technologies Ltd Dexcel, Rakhi Kumar, Richard Pulik, Sciences Ltd Roivant, Svf Investments (Uk) Ltd and Vivek Ramaswamy.
View institutional ownership trends
.

How do I buy shares of Roivant Sciences?

Shares of ROIV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Roivant Sciences' stock price today?

One share of ROIV stock can currently be purchased for approximately $9.77.

How much money does Roivant Sciences make?

Roivant Sciences (NASDAQ:ROIV) has a market capitalization of $7.41 billion and generates $55.29 million in revenue each year. The company earns $-845,260,000.00 in net income (profit) each year or ($1.78) on an earnings per share basis.

How many employees does Roivant Sciences have?

The company employs 620 workers across the globe.

How can I contact Roivant Sciences?

Roivant Sciences' mailing address is Clarendon House, 2 Church Street, Hamilton Parish HM 11. The official website for the company is roivant.com. The company can be reached via phone at 44-20-7400-3347.

This page (NASDAQ:ROIV) was last updated on 6/7/2023 by MarketBeat.com Staff

My Account -